Feedback
Cancer Panel, Hereditary, Sequencing and Deletion/Duplication, 47 Genes
2012032
Ordering Recommendation

Confirm diagnosis of a hereditary cancer syndrome with personal or family history consistent with features of more than one cancer syndrome.

Mnemonic
CANCERPAN
Methodology
Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray
Performed
Varies
Reported
10-12 weeks
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA) or yellow (ACD Solution A or B). 
Specimen Preparation
Transport 3 mL whole blood. (Min: 1 mL) 
Storage/Transport Temperature
Refrigerated 
Unacceptable Conditions
 
Remarks
 
Stability
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable 
Reference Interval
By report
Interpretive Data
Refer to report

Compliance Statement C: The performance characteristics of this test were validated by ARUP Laboratories. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. However, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. ARUP is authorized under Clinical Laboratory Improvement Amendments (CLIA) and by all states to perform high-complexity testing. Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note
Genes tested by Sequencing: ALK, APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN1B,  CDKN2A, CHEK2 common mutations, FH, FLCN, MAX, MEN1, MET, MLH1, MSH2, MSH6, MUTYH, NBN, NF2, PALB2, PHOX2B, PMS2, PTEN, RAD51C, RAD51D, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCB1,STK11, SUFU, TMEM127, TSC1, TSC2, TP53, VHL

Genes tested by Deletion/Duplication: ALK, APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN1B,  CDKN2A, CHEK2 common mutations, EPCAM deletion only, FH, FLCN, MAX, MEN1, MET, MLH1, MSH2, MSH6, MUTYH, NBN, NF2, PALB2, PHOX2B, PMS2, PTEN, RAD51C, RAD51D, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCB1,STK11, SUFU, TMEM127, TSC1, TSC2, TP53, VHL

New York DOH approval pending. Call for status update.
CPT Code(s)
81432; 81433; 81435; 81436; 81437; 81438
Components
Component Test Code*Component Chart NameLOINC
2012033Cancer Panel, Hereditary, Spcm31208-2
2012034Cancer Panel, Hereditary, Interp35474-6
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • PALB2, PHOX2B, PMS2, PTEN, RAD51C, RAD51D, RB1, RET, SDHAF2
  • ALK, APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN1B, CDKN2A
  • CHEK2 common mutations
  • EPCAM deletion only
  • FH, FLCN, MAX, MEN1, MET, MLH1, MSH2, MSH6, MUTYH, NBN, NF2
  • SDHB, SDHC, SDHD, SMAD4, SMARCB1,STK11, SUFU, TMEM127, TSC1, TSC2, TP53, VHL